The sale is part of Sanofi’s strategy to simplify its consumer healthcare portfolio and advance its growth
France-based Sanofi has agreed to divest eight of its consumer healthcare products sold in Latin America to Brazil-based Hypera Pharma for an undisclosed amount.
The agreement also includes the sale of four prescription products from the company’s General Medicine portfolio.
The French pharmaceutical company said that the divestiture is part of its strategy to simplify its consumer healthcare portfolio and advance its growth.
The transaction is expected to be completed by the year-end, subject to certain customary closing conditions and relevant regulatory approvals.
Sanofi executive vice-president and consumer healthcare head Julie Van Ongevalle said: “As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers.
“We are pleased these products will continue to be available for consumers as we focus on becoming a fully integrated standalone business.”
Hypera Pharma is a large-scale pharmaceutical company in Brazil, operating in three major business areas, Branded Prescription, Consumer Health and Branded Generics.
It has established Hynova, an advanced pharmaceutical research centre, to develop pharmaceuticals, dermo-cosmetics and health products in Brazil.
Sanofi is a biopharmaceutical company engaged in research and development, manufacturing and marketing of pharmaceutical drugs.
It covers seven major therapeutic areas, including the cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines.
Last month, Sanofi agreed with German pharmaceutical firm Stada Arzneimittel to divest 16 consumer healthcare brands commercialised in Europe.
Recently, Sanofi and GlaxoSmithKline (GSK) received the regulatory approval for a late-stage clinical trial of their experimental Covid-19 vaccine in India.
The companies started the global phase 3 clinical study in May this year to evaluate the safety, efficacy, and immunogenicity of their Covid-19 vaccine.